Jung Im-Hee, Lee Si-Ho, Jun Choong-Man, Oh Namsik, Yun Jeong-Ho
Department of Dentistry, School of Medicine, Inha University , Incheon, Republic of Korea.
Tissue Eng Part A. 2014 Aug;20(15-16):2189-99. doi: 10.1089/ten.TEA.2013.0648. Epub 2014 Mar 25.
Human periodontal ligament stem cells (hPDLSCs) are considered an appropriate cell source for therapeutic strategies. The aims of this study were to investigate the sustainability of bone morphogenetic protein 2 (BMP2) secretion and the bone regenerative capacity of hPDLSCs that had been genetically modified to express the gene encoding BMP2 (BMP2). hPDLSCs isolated from healthy third molars were transduced using replication-deficient recombinant adenovirus (rAd) encoding BMP2 (hPDLSCs/rAd-BMP2), and the cellular characteristics and osteogenic potentials of hPDLSCs/rAd-BMP2 were analyzed both in vitro and in vivo. hPDLSCs/rAd-BMP2 successfully secreted BMP2, formed colonies, and expressed immunophenotypes similar to their nontransduced counterparts. As to their osteogenic potential, hPDLSCs/rAd-BMP2 formed greater mineralized nodules and exhibited significantly higher levels of expression of BMP2 and the gene encoding alkaline phosphatase, and formed more and better quality bone than other hPDLSC-containing or recombinant human BMP2-treated groups, being localized at the initial site until 8 weeks. The findings of the present study demonstrate that hPDLSCs/rAd-BMP2 effectively promote osteogenesis not only in vitro but also in vivo. The findings also suggest that hPDLSCs can efficiently carry and deliver BMP2, and that hPDLSCs/rAd-BMP2 could be used in an attractive novel therapeutic approach for the regeneration of deteriorated bony defects.
人牙周膜干细胞(hPDLSCs)被认为是治疗策略中合适的细胞来源。本研究的目的是调查经基因改造以表达编码骨形态发生蛋白2(BMP2)的基因的hPDLSCs分泌BMP2的可持续性以及骨再生能力。从健康的第三磨牙分离出的hPDLSCs使用编码BMP2的复制缺陷型重组腺病毒(rAd)进行转导(hPDLSCs/rAd-BMP2),并在体外和体内分析hPDLSCs/rAd-BMP2的细胞特征和成骨潜能。hPDLSCs/rAd-BMP2成功分泌BMP2,形成集落,并表达与其未转导的对应物相似的免疫表型。至于它们的成骨潜能,hPDLSCs/rAd-BMP2形成更大的矿化结节,并表现出BMP2和编码碱性磷酸酶的基因的表达水平显著更高,并且比其他含hPDLSCs或重组人BMP2处理的组形成更多且质量更好的骨,在8周前定位在初始部位。本研究的结果表明,hPDLSCs/rAd-BMP2不仅在体外而且在体内均有效促进成骨。研究结果还表明,hPDLSCs可以有效地携带和递送BMP2,并且hPDLSCs/rAd-BMP2可用于一种有吸引力的新型治疗方法,用于修复恶化的骨缺损。